Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Cimetidine: Distinct H2 Receptor Antagonist for Cancer & ...

    2026-03-12

    Cimetidine: Distinct H2 Receptor Antagonist for Cancer & CNS Research

    Executive Summary: Cimetidine (SKU B1557) is a histamine-2 (H2) receptor antagonist with partial agonist activity, enabling nuanced modulation of H2 receptor signaling pathways in research contexts [APExBIO Product]. Its solubility (≥12.62 mg/mL in DMSO, ≥2.54 mg/mL in water with warming, ≥9.37 mg/mL in ethanol) and validated purity (~98% by HPLC/NMR) underpin reliable, reproducible experimental outcomes. Cimetidine’s pharmacological profile is distinct from other H2 antagonists, such as ranitidine and famotidine, supporting advanced studies in gastric acid secretion inhibition and antitumor activity, particularly in gastrointestinal cancer models [Internal Review]. Emerging CNS research leverages Cimetidine’s compatibility with new blood-brain barrier (BBB) models, enhancing workflow integration for drug permeability screening (Hu et al., 2025). The product is supplied for research use only and should be stored at -20°C for optimal stability.

    Biological Rationale

    Cimetidine was introduced as a first-in-class H2 receptor antagonist, targeting the histamine-2 receptor in gastric parietal cells to inhibit acid secretion. Unlike other H2 antagonists, Cimetidine exhibits partial agonist activity at the H2 receptor, allowing it to modulate, rather than simply block, receptor signaling [See in-depth mechanism]. This feature has expanded its relevance beyond gastroenterology into cancer and CNS research. Researchers employ Cimetidine to dissect H2 receptor signaling, which is implicated in tumor microenvironment modulation and immune responses in gastrointestinal cancers. Furthermore, its physicochemical properties and consistent performance underpin its use in cell viability and blood-brain barrier models [Cell Assay Solutions]. This article clarifies how Cimetidine's distinct profile supports these advanced applications, extending prior reviews by integrating the latest permeability and antitumor findings.

    Mechanism of Action of Cimetidine

    Cimetidine selectively binds to the histamine-2 receptor (H2R), which is a G protein-coupled receptor expressed primarily in gastric parietal cells and variably in other tissues, including certain tumor cells. As a partial agonist, Cimetidine can both inhibit and subtly activate H2R, depending on context and concentration [Pharmacological Profile]. Inhibition of H2R leads to a reduction in cyclic AMP (cAMP) levels, resulting in decreased gastric acid secretion. In cancer models, blockade or modulation of H2R signaling is linked to altered immune cell infiltration, tumor growth, and angiogenesis. The partial agonist effect of Cimetidine distinguishes its cellular and systemic impact from full antagonists like ranitidine and famotidine, which is key in research contexts where nuanced modulation is necessary. This mechanistic diversity is critical for studies exploring both H2R-dependent signaling pathways and the broader tumor microenvironment.

    Evidence & Benchmarks

    • Cimetidine demonstrates high solubility in DMSO (≥12.62 mg/mL), ethanol (≥9.37 mg/mL), and water with gentle warming (≥2.54 mg/mL) (APExBIO Product Sheet, product link).
    • Cimetidine’s purity is independently verified at ~98% by HPLC and NMR, ensuring reproducibility in sensitive assays (APExBIO, product link).
    • As a partial agonist, Cimetidine demonstrates a distinct pharmacological profile, not fully mimicked by ranitidine or famotidine (Internal Review, link).
    • In gastrointestinal cancer research, Cimetidine exhibits measurable antitumor activity, attributed to modulation of the tumor immune microenvironment (Internal Review, link).
    • In blood-brain barrier (BBB) permeability models, Cimetidine is utilized as a reference compound to gauge transporter-mediated and passive diffusion mechanisms (Hu et al., 2025, DOI).
    • The LLC-PK1-MOCK/MDR1 surrogate BBB model, validated with Cimetidine, achieves TEER >70 Ω·cm2 and discriminates P-gp substrates from passive permeants (Hu et al., 2025, DOI).
    • Cimetidine’s optimal storage is at -20°C; prepared solutions are recommended for short-term use to preserve stability (APExBIO, product link).

    Applications, Limits & Misconceptions

    Cimetidine is widely used in research on gastric acid secretion, H2 receptor signaling, cancer biology, and blood-brain barrier permeability. Its reproducible solubility and validated purity support use in sensitive cell-based and biochemical assays [Workflow Guide]. This article extends previous workflow-focused reviews by integrating mechanistic and CNS permeability insights.

    Researchers leverage Cimetidine for the following key applications:

    • Investigating H2 receptor-mediated gastric acid secretion and its inhibition.
    • Dissecting partial agonist effects in gastrointestinal cancer models.
    • Benchmarking passive versus transporter-mediated permeability in in vitro BBB models.
    • Serving as a reference compound in CNS drug screening workflows.

    Common Pitfalls or Misconceptions

    • Not a substrate for all BBB transporters: Cimetidine does not universally interact with every blood-brain barrier efflux or influx transporter, limiting its utility as a pan-BBB probe (Hu et al., 2025, DOI).
    • Not interchangeable with ranitidine or famotidine: Its partial agonist activity and antitumor effects are not reproduced by other H2 antagonists (Internal Review, link).
    • Not for diagnostic or clinical use: APExBIO supplies Cimetidine strictly for research purposes, and it should not be used in human or veterinary medicine.
    • Solution stability is limited: Prepared solutions are recommended for short-term use, as extended storage may reduce activity or purity (APExBIO, product link).
    • Antitumor effects context-specific: Cimetidine’s antitumor properties are best demonstrated in gastrointestinal models and may not generalize to other cancer types.

    Workflow Integration & Parameters

    For optimal experimental reproducibility, Cimetidine should be dissolved in DMSO (≥12.62 mg/mL), ethanol (≥9.37 mg/mL), or water with gentle warming and ultrasonication (≥2.54 mg/mL). Store the solid at -20°C and use prepared solutions promptly. APExBIO ensures batch-to-batch consistency, with lot-specific purity data provided via HPLC and NMR. In blood-brain barrier models, Cimetidine can be used to probe passive versus transporter-mediated permeability, as demonstrated in the LLC-PK1-MOCK/MDR1 system (TEER >70 Ω·cm2, in vitro-to-in vivo correlation R = 0.89) (Hu et al., 2025). For cell viability, proliferation, and cancer signaling workflows, refer to the B1557 kit documentation and workflow guides [Cimetidine product page]. This article updates earlier guides by highlighting recent advances in CNS and BBB permeability modeling.

    Conclusion & Outlook

    Cimetidine offers a unique combination of partial H2 receptor agonism, validated purity, and reproducible solubility, distinguishing it from traditional H2 antagonists. Its proven antitumor activity and compatibility with modern blood-brain barrier models enable advanced research in both cancer and CNS drug discovery. For reliable, mechanistically nuanced experimental outcomes, APExBIO’s Cimetidine (SKU B1557) remains a benchmark standard. Ongoing improvements in in vitro BBB models and expanded mechanistic studies will further clarify the boundaries of Cimetidine’s utility in translational research.